Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07806630) titled 'SHORTened Duration of TAMoxifen' on Sept. 1.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Rutgers, The State University of New Jersey

Condition: High Risk for Invasive Breast Cancer

Intervention: Drug: Tamoxifen

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: September 1, 2026

Target Sample Size: 250

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07806630

Disclaimer: Curated by HT Syndication....